Immune Pharma (IMNP) Reports Q1 Loss of $0.15/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Chardan Capital Lifts PT on Immune Pharma (IMNP) to $6 Following Q1 Report; AmiKet Appears on Track
May 18, 2015 10:14 AM EDTChardan Capital boosts its price target on Immune Pharmaceuticals, Inc. (Nasdaq: IMNP) from $5 to $6 an affirmed its Buy rating on the stock following Q1 results.
Gbola Amusa, MD, CFA, offered the following commentary: We update our model post 1Q15 results, increasing EPS... More
